Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Indian Journal of Surgery
Erschienen in: Indian Journal of Surgery 6/2023

20.02.2023 | Review Article

Cancer Biomarkers: Status and Its Future Direction

verfasst von: Tongbram Malemnganbi Chanu, Lakhon Kma, R. N. Sharan

Erschienen in: Indian Journal of Surgery | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Biomarkers are helpful for disease diagnosis, monitoring disease progression, predicting disease recurrence, treatment monitoring, and efficacy, especially in the domain of cancer management and therapeutics. Clinical cancer biomarker utilization is progressively increasing with increase in and better access to healthcare by the growing populations worldwide. Early cancer detection and therapeutics enhancement remain at the core to increase our cancer management and control abilities. A biomarker can help detect cancer at an early stage as well as aid the clinicians in individualization of therapeutics enhancing the clinical efficacy of cancer therapy. Over the years, several biomarkers have been established and are in regular use. Nonetheless, discovering new cancer biomarkers, which are more sensitive, specific, and clinically convenient, remains important. The current review critically analyzes the existing and established cancer biomarkers as well as futuristic biomarkers for clinicians, surgeons, oncologists, and researchers. A tabular summary at the end of the article and compilation of up to date literature in the domain should be useful ready reckoners for clinicians, oncologists, and researchers alike.
Literatur
1.
Lassere MN (2008) The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. Stat Methods Med Res 17:303–340PubMedCrossRef
2.
World Health Organization & International Programme on Chemical Safety (1993) Biomarkers and risk assessment: concepts and principles / published under the joint sponsorship of the United Nations environment Programme, the International Labour Organisation, and the World Health Organization. WHO https://​apps.​who.​int/​iris/​handle/​10665/​39037
3.
4.
Simon R, Roychowdhury S (2013) Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov 12:358–369PubMedCrossRef
5.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672PubMedCrossRef
6.
Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D’Haens G, Pintér T, Lim R, Bodoky G, Roh JK (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417PubMedCrossRef
7.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826PubMedCrossRef
8.
Coleman RL, Herzog TJ, Chan DW, Munroe DG, Pappas TC, Smith A, Zhang Z, Wolf J (2016) Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses. Am J Obstet Gynecol 215:82–93CrossRef
9.
10.
11.
12.
13.
Nora MAA, Connor T, Ishwarlal J (2021) Genetics, epigenetic mechanism. StatPearls
14.
15.
16.
17.
18.
AlSalloom AAM (2016) An update of biochemical markers of hepatocellular carcinoma. Int J Health Sci 10:121–136
19.
Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J (2013) α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatol 58:1253–1262CrossRef
20.
Albrecht H, Carraway KL (2011) MUC1 and MUC4: switching the emphasis from large to small. Cancer Biother Radiopharm 26:261–271PubMedPubMedCentral
21.
Mukhopadhyay P, Chakraborty S, Ponnusamy MP, Lakshmanan I, Jain M, Batra SK (2011) Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim Biophys Acta 1815:224–240PubMedPubMedCentral
22.
Mudduwa LK, Wijayaratne GB, Peiris HH, Gunasekera SN, Abeysiriwardhana D, Liyanage N (2018) Elevated pre-surgical CA15-3: does it predict the short-term disease-free survival of breast cancer patients without distant metastasis? Int J Women Health 10:329–335CrossRef
23.
Duffy MJ, Evoy D, McDermott EW (2010) CA 15–3: uses and limitation as a biomarker for breast cancer. Clin Chim Acta 411:1869–1874PubMedCrossRef
24.
Perkins GL, Slater ED, Sanders GK, Prichard JG (2003) Serum tumor markers. Am Fam Physician 68:1075–1082PubMed
25.
Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P (1979) Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 5:957–971PubMedCrossRef
26.
27.
Kim S, Park BK, Seo JH, Choi J, Choi JW, Lee CK, Chung JB, Park Y, Kim DW (2020) Carbohydrate antigen 19–9 elevation without evidence of malignant or pancreatobiliary diseases. Sci Rep 10:1–9
28.
Ballehaninna UK, Chamberlain RS (2012) The clinical utility of serum CA 19–9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol 3:105–119PubMedPubMedCentral
29.
Kabel AM (2017) Tumor markers of breast cancer: new perspectives. J Oncol Sci 3:5–11CrossRef
30.
Vaidyanathan K, Vasudevan DM (2012) Organ specific tumor markers: what’s new? Indian J Clin Biochem 27:110–120PubMedCrossRef
31.
32.
Lin DC, Genzen JR (2018) Concordance analysis of paired cancer antigen (CA) 15–3 and 27.29 testing. Breast Cancer Res Treat 167:269–276PubMedCrossRef
33.
Muinao T, Boruah HP, Pal M (2018) Diagnostic and prognostic biomarkers in ovarian cancer and the potential roles of cancer stem cells - an updated review. Exp Cell Res 362:1–10PubMedCrossRef
34.
35.
Pepin K, Carmen MD, Brown A, Dizon DS (2014) CA 125 and epithelial ovarian cancer: role in screening, diagnosis, and surveillance. Am J Hematol 10:22–29
36.
Rustin GJ, Bast RC, Kelloff GJ, Barrett JC, Carter SK, Nisen PD, Sigman CC, Parkinson DR, Ruddon RW (2004) Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 10:3919–3926PubMedCrossRef
37.
Pignata S, Cannella L, Leopardo D, Bruni GS, Facchini G, Pisano C (2011) Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up. Ann Oncol 22:viii40–viii44
38.
Bast RC Jr (2010) CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer 116:2850–2853PubMedCrossRef
39.
Gold P, Freedman SO (1965) Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 121:439–462PubMedPubMedCentralCrossRef
40.
Zhong W, Yu Z, Zhan J, Yu T, Lin Y, Xia ZS, Yuan YH, Chen QK (2015) Association of serum levels of CEA, CA199, CA125, CYFRA21-1 and CA72-4 and disease characteristics in colorectal cancer. Pathol Oncol Res 21:83–95PubMedCrossRef
41.
Saito G, Sadahiro S, Kamata H, Miyakita H, Okada K, Tanaka A, Suzuki T (2017) Monitoring of serum carcinoembryonic antigen levels after curative resection of colon cancer: cut off values determined according to preoperative levels enhance the diagnostic accuracy for recurrence. Oncology 92:276–282PubMedCrossRef
42.
Xie HL, Gong YZ, Kuang JA, Gao F, Tang SY, Gan JL (2019) The prognostic value of the postoperative serum CEA levels/preoperative serum CEA levels ratio in colorectal cancer patients with high preoperative serum CEA levels. Cancer Manag Res 11:7499–7511PubMedPubMedCentralCrossRef
43.
Sørensen CG, Karlsson WK, Pommergaard HC, Burcharth J, Rosenberg J (2016) The diagnostic accuracy of carcinoembryonic antigen to detect colorectal cancer recurrence–a systematic review. Int J Surg 25:134–144PubMedCrossRef
44.
Wang Z, Wang W, Xu S, Wang S, Tu Y, Xiong Y, Mei J, Wang C (2016) The role of MAPK signaling pathway in the Her-2-positive meningiomas. Oncol Rep 36:685–695PubMedPubMedCentralCrossRef
45.
Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R (2015) HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev 34:157–164PubMedPubMedCentralCrossRef
46.
47.
Wang XY, Zheng ZX, Sun Y, Bai YH, Shi YF, Zhou LX, Yao YF, Wu AW, Cao DF (2019) Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas. World J Gastrointest Oncol 11:335–347PubMedPubMedCentralCrossRef
48.
Ferraro S, Panteghini M (2019) Making new biomarkers a reality: the case of serum human epididymis protein 4. Clin Chem Lab Med 57:1284–1294PubMedCrossRef
49.
Lu R, Sun X, Xiao R, Zhou L, Gao X, Guo L (2012) Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility. Biochem Biophys Res Commun 419:274–280PubMedCrossRef
50.
Zhu L, Zhuang H, Wang H, Tan M, Schwab CL, Deng L, Gao J, Hao Y, Li X, Gao S, Liu J (2016) Overexpression of HE4 (human epididymis protein 4) enhances proliferation, invasion and metastasis of ovarian cancer. Oncotarget 7:729–744PubMedCrossRef
51.
Moradi A, Srinivasan S, Clements J, Batra J (2019) Beyond the biomarker role: prostate-specific antigen (PSA) in the prostate cancer microenvironment. Cancer Metastasis Rev 38:333–346PubMedCrossRef
52.
53.
Siemińska L, Borowski A, Marek B, Nowak M, Kajdaniuk D, Warakomski J, Kos-Kudła B (2018) Serum concentrations of adipokines in men with prostate cancer and benign prostate hyperplasia. Endokrynol Pol 69:120–127PubMed
54.
Duffy MJ (2020) Biomarkers for prostate cancer: prostate-specific antigen and beyond. Clin Chem Lab Med 58:326–339PubMedCrossRef
55.
Tamhane S, Gharib H (2016) Thyroid nodule update on diagnosis and management. Clin Diabetes Endocrinol 2:1–10
56.
Prpić M, Franceschi M, Romić M, Jukić T, Kusić Z (2018) Thyroglobulin as a tumor marker in differentiated thyroid cancer–clinical considerations. Acta Clin Croat 57:518–526PubMedPubMedCentral
57.
58.
Ueland FR, Desimone CP, Seamon LG, Miller RA, Goodrich S, Podzielinski I, Sokoll L, Smith A, Van Nagell Jr JR, Zhang Z (2011) Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol 117:1289–1297PubMedCrossRef
59.
Zhang Z, Chan DW (2010) The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomarkers Prev 19:2995–2999PubMedPubMedCentralCrossRef
60.
Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC Jr, Skates SJ (2009) A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112:40–46PubMedCrossRef
61.
Anton C, Carvalho FM, Oliveira EI, Maciel GA, Baracat EC, Carvalho JP (2012) A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics 67:437–441PubMedPubMedCentralCrossRef
62.
Wang J, Gao J, Yao H, Wu Z, Wang M, Qi J (2014) Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis. Tumor Biol 35:6127–6138CrossRef
63.
Al Musalhi K, Al Kindi M, Al Aisary F, Ramadhan F, Al Rawahi T, Al Hatali K, Mula-Abed WA (2016) Evaluation of HE4, CA-125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) in the preoperative assessment of patients with adnexal mass. Oman Med J 31:336–344PubMedPubMedCentralCrossRef
64.
Sharan RN (2009) 15 poly-ADP-ribosylation in cancer. In: Trygve Tollefsbol (ed) Cancer Epigenetics. CRC Press, Florida, pp 265–279
65.
Chanu TM (2022) PhD thesis entitled Clinical correlation between cancer regression and selected genetic and epigenetic biomarkers in patients undergoing cancer therapy. NEHU, Shillong, India
66.
Sharan RN, Devi BJ, Humtsoe JO, Saikia JR, Kma L (2005) Detection and quantification of poly-ADP-ribosylated cellular proteins of spleen and liver tissues of mice in vivo by slot and Western blot immunoprobing using polyclonal antibody against mouse ADP-ribose polymer. Mol Cell Biochem 278:213–221PubMedCrossRef
67.
Devi BJ, Schneeweiss FHA, Sharan RN (2005) Negative correlation between poly-ADP-ribosylation of spleen cell histone proteins and initial duration of dimethylnitrosamine exposure to mice in vivo measured by Western blot immunoprobe assay: a possible biomarker for cancer detection. Cancer, Detect Prev 29:66–71PubMedCrossRef
68.
Saikia JR, Schneeweiss FHA, Sharan RN (1998) Effects of chronic low-dose arecoline administration on the macromolecular components of bone marrow and spleen cells of mice. Cancer J 11:94–98
69.
Kma L, Sharan RN (2014) Dimethylnitrosamine induced reduction in the level of poly- ADP ribosylation of histone proteins of blood lymphocytes – a sensitive and reliable biomarker for early detection of cancer. Asia Pac J Cancer Prev 15:6429–6436CrossRef
70.
71.
Hoxhaj G, Manning BD (2020) The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer 20:74–88PubMedCrossRef
72.
73.
Turner KM, Sun Y, Ji P, Granberg KJ, Bernard BL, Cogdell DE, Zhou X, Yli-Harja O, Nykter M, Shmulevich I (2015) Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression. Proc Natl Acad Sci 112:3421–3426PubMedPubMedCentralCrossRef
74.
75.
Guo K, Tang W, Zhuo H, Zhao G (2019) Recent advance of Akt inhibitors in clinical trials. ChemistrySelect 4:9040–9044CrossRef
76.
77.
Huang F, Goyal N, Sullivan K, Hanamshet K, Patel M, Mazina OM, Wang CX, An WF, Spoonamore J, Metkar S, Emmitte KA (2016) Targeting BRCA1-and BRCA2-deficient cells with RAD52 small molecule inhibitors. Nucleic Acid Res 44:4189–4199PubMedPubMedCentralCrossRef
78.
Jin TY, Park KS, Nam SE, Yoo YB, Park WS, Yun IJ (2022) BRCA1/2 serves as a biomarker for poor prognosis in breast carcinoma. Intl J Mol Sci 23:3754–3768CrossRef
79.
Mazin AV, Zaitseva E, Sung P, Kowalczykowski SC (2000) Tailed duplex DNA is the preferred substrate for Rad51 protein-mediated homologous pairing. EMBO J 19:1148–1156PubMedPubMedCentralCrossRef
80.
Dutto I, Scalera C, Prosperi E (2018) CREBBP and p300 lysine acetyl transferases in the DNA damage response. Cell Mol Life Sci 75:1325–1338PubMedCrossRef
81.
Karimian A, Ahmadi Y, Yousefi B (2016) Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair 42:63–71PubMedCrossRef
82.
83.
84.
Moor NA, Lavrik OI (2018) Protein–protein interactions in DNA base excision repair. Biochemistry 83:411–422PubMed
85.
Weiss RH, Borowsky AD, Seligson D, Lin PY, Dillard-Telm L, Belldegrun AS, Figlin RA, Pantuck AD (2007) p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol 177:63–69PubMedCrossRef
86.
87.
88.
Ciocca DR, Calderwood SK (2005) Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10:86–103PubMedPubMedCentralCrossRef
89.
Lianos GD, Alexiou GA, Mangano A, Rausei S, Boni L, Dionigi G, Roukos DH (2015) The role of heat shock proteins in cancer. Cancer Lett 360:114–118PubMedCrossRef
90.
Moon A, Bacchini P, Bertoni F, Olvi LG, Santini-Arawo E, Kim YW, Par YK (2010) Expression of heat shock proteins in osteosarcomas. Pathology 42:421–425PubMedCrossRef
91.
92.
Wang W, Xu X, Tian B, Wang Y, Du L, Sun T, Shi Y, Zhao X, Jing J (2017) The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer. Clin Chim Acta 470:51–55PubMedCrossRef
93.
94.
95.
Conciatori F, Ciuffreda L, Bazzichetto C, Falcone I, Pilotto S, Bria E, Cognetti F, Milella M (2018) mTOR cross-talk in cancer and potential for combination therapy. Cancers 10:23–34PubMedPubMedCentralCrossRef
96.
Zou Z, Tao T, Li H, Zhu X (2020) mTOR signaling pathway and mTOR inhibitors in cancer: Progress and challenges. Cell Biosci 10:1–10CrossRef
97.
Lee HK, Lee DS, Park JC (2015) Nuclear factor IC regulates E-cadherin via control of KLF4 in breast cancer. BMC Cancer 15:1–11CrossRef
98.
Grabowska MM, Elliott AD, DeGraff DJ, Anderson PD, Anumanthan G, Yamashita H, Sun Q, Friedman DB, Hachey DL, Yu X, Sheehan JH (2014) NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression. Mol Endocrinol 28:949–964PubMedPubMedCentralCrossRef
99.
Fane M, Harris L, Smith AG, Piper M (2017) Nuclear factor one transcription factors as epigenetic regulators in cancer. Int J Cancer 140:2634–2641PubMedCrossRef
100.
101.
Zenker M, Bunt J, Schanze I, Schanze D, Piper M, Priolo M, Gerkes EH, Gronostajski RM, Richards LJ, Vogt J, Wessels MW (2019) Variants in nuclear factor I genes influence growth and development. Am J Med Gen 181:611–626CrossRef
102.
103.
Hegde PS, Wallin JJ, Mancao C (2018) Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol 52:117–124PubMedCrossRef
104.
Kulapaditharom B, Boonkitticharoen V, Sritara C (2012) Plasma vascular endothelial growth factor dysregulation in defining aggressiveness of head and neck squamous cell carcinoma. J Oncol 15:12–20
105.
Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL (2020) Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev 86:102–117CrossRef
Metadaten
Titel
Cancer Biomarkers: Status and Its Future Direction
verfasst von
Tongbram Malemnganbi Chanu
Lakhon Kma
R. N. Sharan
Publikationsdatum
20.02.2023
Verlag
Springer India
Erschienen in
Indian Journal of Surgery / Ausgabe 6/2023
Print ISSN: 0972-2068
Elektronische ISSN: 0973-9793
DOI
https://doi.org/10.1007/s12262-023-03723-1

Weitere Artikel der Ausgabe 6/2023

Indian Journal of Surgery 6/2023 Zur Ausgabe

Editorial

When Should Surgeons Retire?

Letter to Editor

A Search for Locked ORCIDs Reveals a Batch of Odd Accounts

Images in Surgery

A Rare Pseudotumour—Hypertrophy of the Tensor Fascia Lata

Case Report

Retroperitoneal Necrotizing Fasciitis: A Rare Surgical Emergency

Original Article

Prognostic Impacts of the Localization and Diameter of Breast Cancer Axillary Micrometastasis

Case Report

Gestational Gigantomastia: a Case Report

Neu im Fachgebiet Chirurgie

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.
Bildnachweise